Published in J Hematol Oncol on April 17, 2017
Recent advances of highly selective CDK4/6 inhibitors in breast cancer. J Hematol Oncol (2017) 0.77
Pathway-based discovery of genetic interactions in breast cancer. PLoS Genet (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Cancer statistics, 2016. CA Cancer J Clin (2016) 32.95
Learning the parts of objects by non-negative matrix factorization. Nature (1999) 21.77
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
lumi: a pipeline for processing Illumina microarray. Bioinformatics (2008) 17.19
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A (2004) 10.47
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev (1995) 7.16
Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med (1985) 5.82
Control of mammary stem cell function by steroid hormone signalling. Nature (2010) 5.38
Progesterone induces adult mammary stem cell expansion. Nature (2010) 4.69
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol (2012) 4.14
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev (2000) 3.30
A flexible R package for nonnegative matrix factorization. BMC Bioinformatics (2010) 3.28
A paracrine role for the epithelial progesterone receptor in mammary gland development. Proc Natl Acad Sci U S A (1998) 3.23
Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res (2008) 2.96
Mechanisms of tamoxifen resistance. Endocr Relat Cancer (2004) 2.92
Progesterone receptor modulates ERα action in breast cancer. Nature (2015) 2.85
Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci U S A (2000) 2.69
Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer (2013) 2.60
Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci U S A (2010) 2.45
Sparse non-negative matrix factorizations via alternating non-negativity-constrained least squares for microarray data analysis. Bioinformatics (2007) 2.43
Improving molecular cancer class discovery through sparse non-negative matrix factorization. Bioinformatics (2005) 2.42
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell (2015) 2.39
A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol (1995) 2.20
Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nat Commun (2013) 2.11
Progesterone/RANKL is a major regulatory axis in the human breast. Sci Transl Med (2013) 2.09
Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol (1995) 2.08
Mammary stem cells and the differentiation hierarchy: current status and perspectives. Genes Dev (2014) 1.86
Estrogen and progesterone receptors: correlation of response rates, site and timing of receptor analysis. Breast Cancer Res Treat (1982) 1.81
Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol Cell Biol (2001) 1.70
Steroid receptor phosphorylation: a key modulator of multiple receptor functions. Mol Endocrinol (2007) 1.68
A comprehensive view of nuclear receptor cancer cistromes. Cancer Res (2011) 1.64
DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology (2009) 1.55
Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle (2012) 1.54
Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator. Mol Cell Biol (2005) 1.41
Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol Cell Biol (2004) 1.40
Differential hormone-dependent phosphorylation of progesterone receptor A and B forms revealed by a phosphoserine site-specific monoclonal antibody. Mol Endocrinol (2000) 1.39
Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. Mol Endocrinol (2007) 1.36
Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat (2009) 1.35
Molecular interactions of the aryl hydrocarbon receptor and its biological and toxicological relevance for reproduction. Reproduction (2005) 1.34
Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol Cell Biol (2003) 1.32
Mitogen-activated protein kinase regulates nuclear association of human progesterone receptors. Mol Endocrinol (2003) 1.31
The RUNX family in breast cancer: relationships with estrogen signaling. Oncogene (2012) 1.30
Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet (1981) 1.29
Prognostic effect of estrogen receptor status across age in primary breast cancer. Int J Cancer (2008) 1.26
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res (2014) 1.23
Early dissemination seeds metastasis in breast cancer. Nature (2016) 1.20
Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer (1980) 1.15
MAP kinases couple multiple functions of human progesterone receptors: degradation, transcriptional synergy, and nuclear association. J Steroid Biochem Mol Biol (2003) 1.11
ESCAPE: database for integrating high-content published data collected from human and mouse embryonic stem cells. Database (Oxford) (2013) 1.10
Non-overlapping progesterone receptor cistromes contribute to cell-specific transcriptional outcomes. PLoS One (2012) 1.09
Recruitment of dioxin receptor to active transcription sites. Mol Biol Cell (2002) 1.08
Expression of the PAX2 oncogene in human breast cancer and its role in progesterone-dependent mammary growth. Oncogene (2002) 1.08
Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res (2012) 1.08
Runx2 controls a feed-forward loop between androgen and prolactin-induced protein (PIP) in stimulating T47D cell proliferation. J Cell Physiol (2012) 1.03
Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer. Cancer (1980) 1.00
ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells. Mol Cell Biol (2011) 1.00
Progesterone receptor and Stat5 signaling cross talk through RANKL in mammary epithelial cells. Mol Endocrinol (2013) 1.00
Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. Oncogene (2014) 0.98
Progesterone action in breast, uterine, and ovarian cancers. J Mol Endocrinol (2015) 0.98
Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells. Proc Natl Acad Sci U S A (2009) 0.97
Progesterone and estrogen receptors segregate into different cell subpopulations in the normal human breast. Mol Cell Endocrinol (2012) 0.91
Cross-talk of dioxin and estrogen receptor signals through the ubiquitin system. J Steroid Biochem Mol Biol (2011) 0.91
Tracking progesterone receptor-mediated actions in breast cancer. Pharmacol Ther (2013) 0.91
RUNX2 in mammary gland development and breast cancer. J Cell Physiol (2013) 0.90
Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer (1999) 0.89
Form and Function: how Estrogen and Progesterone Regulate the Mammary Epithelial Hierarchy. J Mammary Gland Biol Neoplasia (2015) 0.88
Role of phosphorylation in progesterone receptor signaling and specificity. Mol Cell Endocrinol (2011) 0.88
Ecotropic viral integration site 1, stem cell self-renewal and leukemogenesis. Cancer Sci (2012) 0.87
Runx2 is a novel regulator of mammary epithelial cell fate in development and breast cancer. Cancer Res (2014) 0.87
RUNX2 correlates with subtype-specific breast cancer in a human tissue microarray, and ectopic expression of Runx2 perturbs differentiation in the mouse mammary gland. Dis Model Mech (2014) 0.87
The Role of Androgen Receptor in Breast Cancer. Drug Discov Today Dis Mech (2012) 0.86
A Common Docking Domain in Progesterone Receptor-B links DUSP6 and CK2 signaling to proliferative transcriptional programs in breast cancer cells. Nucleic Acids Res (2013) 0.85
PAX Genes in Cancer; Friends or Foes? Front Genet (2012) 0.85
Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells. Mol Endocrinol (2014) 0.84
Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy. Breast Cancer Res (2013) 0.83
Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer. Breast Cancer Res Treat (2015) 0.82
Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Ann Oncol (2013) 0.81
The role of the aryl hydrocarbon receptor in the development of cells with the molecular and functional characteristics of cancer stem-like cells. BMC Biol (2016) 0.80
Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. Sci Adv (2016) 0.80
ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy. Endocr Relat Cancer (2016) 0.78
Dynamic regulation of steroid hormone receptor transcriptional activity by reversible SUMOylation. Vitam Horm (2013) 0.77
The Androgen Receptor Bridges Stem Cell-Associated Signaling Nodes in Prostate Stem Cells. Stem Cells Int (2016) 0.76
Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming. Mol Cancer Res (2015) 0.76
The Aryl Hydrocarbon Receptor Relays Metabolic Signals to Promote Cellular Regeneration. Stem Cells Int (2016) 0.76
Heregulin Co-opts PR Transcriptional Action Via Stat3 Role As a Coregulator to Drive Cancer Growth. Mol Endocrinol (2015) 0.76